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Introduction
Obstructive sleep apnea (OSA) is a chronic, highly prevalent 
sleep disorder, with recent prevalence estimates of around 
22% in men and 17% in women (1). Despite progress in 
raising public awareness of OSA, it remains underdiagnosed 
in the general population (2,3). Episodes of intermittent 
hypoxia (IH) and sleep fragmentation occur during nocturnal 
cycles of pharyngeal collapse, leading to a cascade of adaptive 
and maladaptive processes, such as systemic inflammation, 
endothelial dysfunction, and oxidative stress (3-5). Whilst 
the association of OSA with cardiovascular and metabolic 
co-morbidities is well recognised and described (6,7), its 
potential role in brain injury, leading to or aggravating 
existent neurological/psychiatric and neurodegenerative 
disorders, has only recently started receiving significant 
attention (5,8). Similarly, its potential role in the etiology 
of chronic kidney disease (CKD) and its association with 
cancer are not well understood. These co-morbidities and 
the intricate interplay between OSA and their pathogenesis 
are the main focus of this review.
 
OSA and impaired cognition
A variety of cognitive deficits, such as difficulties with 
attention, memory, executive functioning, and quality of life 
have an established relationship with OSA, alongside a number 
of psychiatric disorders in susceptible patients (8). Some of 
these impairments have been associated with corresponding 
structural changes (9,10). Continuous positive airway 
pressure (CPAP)—still the mainstay of OSA treatment—
has been shown to at least partially reverse some of the 
cognitive impairments and associated neuroanatomical 
changes (8,11-13). 
In addition, difficulty in forming functional interpersonal 
relationships, irritability, decreased work and school 
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efficiency, and proneness to accidents, have all been 
documented in OSA patients (9,14,15). It has been proposed 
that OSA patients are two to thirteen times more likely 
to experience a driving-related traffic accident than the 
general population (16-19). Such accidents are more likely 
to occur in those with greater daytime sleepiness, but they 
are not necessarily related to sleepiness alone (16,20). In 
addition to cognitive and emotional deficits, the prevalence 
of OSA has been reported to be increased in several 
psychiatric disorders (21), with the strongest association 
seen with major depressive disorder (MDD), anxiety, and 
posttraumatic stress disorder (PTSD) (21-23). 
The cognitive impairment seen in OSA tends to be more 
significant with increasing age (24-26), suggesting that older 
age groups are more susceptible to the effects of OSA on 
the brain (27), or that compensatory mechanisms that are 
perhaps present in younger people and help to recruit other 
areas of the brain to maintain performance, may no longer be 
as proficient (28). OSA is increasingly prevalent with age (29), 
although there tends to be less reported sleepiness in older 
patients. More recently, a link between Alzheimer’s disease (AD) 
and OSA has been suggested by a number of studies (30-33), 
with some authors arguing that dysregulated immunological 
mechanisms in the brain in OSA patients may contribute to 
the evolution of AD (9,34,35). 
The results of a recent meta-analysis suggest that subjects 
with AD have an approximately five-fold likelihood of having 
concomitant OSA when compared with healthy controls (33). 
The causal relationship between untreated OSA and 
neurodegenerative processes is, however, unclear (5,9). The 
results of genome-wide analyses have shown that several 
genes that increase the risk for sporadic AD, also encode 
factors that regulate glial clearance of misfolded proteins 
and neuroinflammation (33,34).
It has been suggested that treatment of OSA, particularly 
in the early stages of AD, when patients are still largely 
independent, may decelerate the progression of dementia 
(36,37). CPAP appears to be partially effective in improving 
episodic verbal learning, memory, cognitive flexibility and 
mental processing speed in patients with co-morbid AD 
and OSA (36). Similarly, a study that analysed patients from 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
cohort found a significant association of self-reported sleep-
disordered breathing with an earlier age of onset of mild 
cognitive impairment (31); mild cognitive impairment was 
observed approximately one decade earlier in sleep apnea 
patients, even when accounting for possible confounding 
factors. However, in those patients who used CPAP, this 
link appeared significantly attenuated, suggesting that 
use of CPAP may delay the progression of mild cognitive 
impairment (31). 
Recent neuroimaging studies have suggested that sleep 
disruption and fragmentation provide a mechanism through 
which β-amyloid pathology contributes to hippocampus-
dependent cognitive decline in the elderly (38,39). 
Inadequate sleep and significant sleep fragmentation present 
another important etiological aspect of OSA-induced brain 
injury and may contribute to the acceleration of ‘normal 
aging’ processes in patients with OSA (5). 
Sleep fragmentation and deprivation
In previous studies that have deprived healthy individuals 
of sleep (40-42), sleep deprivation was associated 
with impairment in cortical and white matter regions, 
particularly those that likely underlie functions of attention 
and vigilance. It has been argued that sleep deprivation 
and fragmentation can independently lead to cognitive 
impairment, and in a similar pattern to what has been 
also associated with IH (43,44). Moreover, any significant 
sleep fragmentation likely disrupts restorative homeostatic 
synaptic processes in the brain and further interferes with 
memory consolidation and transformation, contingent on 
which sleep stages are affected (45,46). It also likely further 
precipitates neuroinflammatory processes and aggravates 
any predisposing immunological dysfunction (9,47). In 
a study assessing cognition in patients with untreated 
insomnia, narcolepsy and OSA versus controls, a shared 
impairment in alertness and selective attention, as well 
as decreased visual tracking, was identified (48). These 
findings were also associated with an increase in self-rated 
tiredness and daytime somnolence, and suggest a potential 
common pathological mechanism. Indeed, there is evidence 
that hypersomnolence itself (regardless of its cause) is an 
independent risk factor for cognitive impairment (49). 
Residual cognitive impairment in patients who adhere 
well to their treatment with CPAP suggests a degree of 
irreversibility in some changes induced by OSA, and it likely 
points to importance of early recognition and induction 
of treatment (50,51). Equally, it is possible that CPAP as a 
treatment might not be a universal panacea for all stages 
of this chronic illness, and or that in certain susceptible 
patients CPAP treatment might need to be supplemented 
with other treatment modalities (e.g., antioxidants) in order 
to combat all aspects of neuroinflammation and oxidative 
stress injury induced by OSA (21).
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IH
Hypoxia may affect the structure and function of the 
blood-brain barrier (52), leading to altered microvessel 
permeability and microregional oxidative processes, all of 
which could in the long term alter synaptic plasticity, and 
also contribute to cognitive impairment (3). Several mouse 
models have been used over the years to look at the effects 
of IH on the brain (53). Their results taken together suggest 
that IH leads to oxidative stress, inflammation, and regional 
and distant neuroanatomical and functional changes, 
depending on the severity, frequency and chronicity of the 
insult. IH-induced oxidative injury in the wake-promoting 
basal forebrain and brainstem in mice may lead to persistent 
hypersomnolence and associated cognitive impairment (54). 
Several studies comparing IH and sleep fragmentation in 
animal models have shown that similar brain regions are 
affected by both insults (24,43). 
Apart from maladaptive processes, IH likely also 
starts cascade of adaptive homeostatic processes, such as 
ischaemic preconditioning, in all affected body systems, 
including the brain. Ischaemic pre-conditioning has been 
demonstrated in animal models in numerous body organs 
and systems (55,56). Moreover, it has been shown that 
ischemic insult in animals can lead to adult neurogenesis 
in neurogenic niches such as the dentate gyrus of the 
hippocampus and the olfactory bulb, and in some animals 
also in the striatum (57). Neurogliogenesis secondary to 
IH has also been postulated to occur in patients (58). In a 
recent study, hypertrophy of the hippocampi of patients 
with mild OSA was demonstrated, perhaps suggestive of 
such adaptive processes at work (59), whilst another study 
identified changes in creatine levels in the hippocampus in 
OSA patients, suggesting adjusted bioenergetics similar to 
those seen in ischaemic preconditioning (60). 
Over the last several decades, numerous neuroimaging 
studies in patients with OSA have delineated a putative 
neurocircuitry fingerprint of sleep fragmentation and IH-
induced brain injury (61). This wide circuitry suggests 
disconnection of the frontal regions [also see (21)], and the 
disruption of the (cerebello)-thalamocortical oscillator with 
involvement of the hippocampal formation.
Neuroanatomy of OSA
Historically, a number of voxel based morphometry (VBM) 
studies have investigated areas of the brain affected in 
patients with OSA with diverse regions being highlighted 
as more or less impacted (62-66). An early study assessing 
changes in patients with OSA reported diffuse changes in 
the frontal, temporal and parietal cortices, as well as in the 
anterior cingulate gyrus, hippocampus, and cerebellum (67). 
Subsequently, a combined VBM and PET imaging study 
demonstrated hypotrophic changes in wider circuitry, 
as well as a decrease in cortical metabolism despite no 
clinically overt cognitive deficits being present (64). This 
has been argued to suggest early processes likely leading to 
later clinically measurable cognitive changes. Later studies 
demonstrated the correlation between neuroimaging 
changes and cognitive deficits, including those in executive 
functioning and verbal memory (65,68). 
In a recent comprehensive meta-analysis of functional and 
structural neuroimaging studies (10), structural atrophy and 
functional disturbances in the right basolateral amygdala, the 
hippocampus and the right central insula were demonstrated 
(Figures 1,2). Behavioural analyses of these regions suggested 
associated dysfunction of emotional, sensory and cognitive 
processes (Figure 3), and further highlighted a diffuse 
network within the bilateral anterior insula, posterior-medial 
frontal cortex and thalamus (Figure 4).
The importance of the amygdala as one of structures 
affected by the chronic process of OSA has been previously also 
shown in children (69). In children with OSA, greater neural 
recruitment of regions involved in cognitive control, conflict 
monitoring, and attentional allocation is required in order 
to perform at the same level as children without OSA (69). 
Of further note is that the amygdala has a recognised role 
in the etiology of anxiety disorders, MDD, and PTSD, 
potentially contributing to the increased prevalence of these 
psychopathologies in patients with OSA (10). The activation 
of the amygdala during emotional arousal enhances memory, 
in part by modulating plasticity in the hippocampus. It is 
possible that aberrant functional connectivity of amygdala 
and hippocampus in patients with OSA may further impact 
already dysfunctional intrinsic network activity in MDD, 
and that this may underlie some of the psychological 
disturbances in patients with OSA (10). In a similar vein, 
an aberrant connectivity between the hippocampus and the 
cerebellum, which has been previously reported in OSA 
patients, may lead to alterations in a distributed memory 
system for associative learning (59). On the other hand, an 
atypical engagement of the insula within the salience network 
appears to be common feature of OSA as well as of several 
neuropsychiatric disorders, including AD and MDD (10).
Functional MRI has also been used to show that OSA 
patients display decreased levels of activation in the frontal 
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lobes (28,67), and an increased compensatory activation 
during memory and attention tasks in comparison to 
healthy controls (70,71). This increased activation was lost 
or ameliorated after CPAP treatment (71). 
A beneficial effect of CPAP therapy in the treatment 
of cognitive deficits in subjects with OSA was suggested 
by results of a recent study by Canessa et al. (12). They 
showed that 3 months of CPAP treatment was associated 
with a significant increase in grey matter volume in the 
bilateral hippocampus and frontal structures, which 
correlated with an improvement in executive function, 
memory and attention (12). Similarly, in a recent study that 
used randomised controlled design, one month of CPAP 
treatment resulted in a partial recovery of episodic and 
working-memory capacity (Figure 4) (13). The observed 
thalamocortical changes were associated with changes in 
bilateral hippocampi and cerebellar cortices (13). These data 
suggest that a relatively short period of CPAP treatment 
may allow rudimentary neuroplastic changes to occur within 
targeted brain structures of patients with moderate to severe 
Figure 1 Convergence of structural and functional difference in obstructive sleep apnea compared with healthy controls (10). Location of 
the significant convergence of gray matter reduction and functional disturbance in the right basolateral nucleus of the human amygdala and 
the hippocampus (P<0.05, cFWE corrected) (A) and in the right central insula (P<0.05, cFWE corrected) (B) (10).
A B
Figure 2 Behavioral characterization of the significant cluster in the right amygdala/hippocampus (A) and in the right central insula (B) 
which is shown affected in sleep apnea patients (10).
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Figure 4 Schematic presentation of the neuroarchitecture behind working memory maintenance processes that might be implicated in 
improved daytime somnolence and verbal episodic memory by the CPAP treatment (13). Distributed nature of processes and representations 
involved to solve working-memory tasks is shown, with thalamus (central structure) acting as a functional interface between arousal and 
attentional regulation. The hippocampus (elongated green), is the structure most frequently reported affected by neuroimaging in OSA, 
here it is proposed to bind aspects of working and episodic memory. The list of cognitive tests used to investigate impact of CPAP treatment 
on associated cognitive domains is shown. CPAP treatment leads to improvement in verbal episodic memory (green box), which may be due 
to the interplay of the cascade of gradual changes in the semantic and verbal working memory. In addition, CPAP leads to the improvement 
of excessive daytime somnolence (yellow box), which in turn appears to be significantly, correlated to ensuing brainstem alterations (13). 
CPAP, continuous positive airway pressure; BSC, best supportive care; LTM, long term memory; ESS, Epworth Sleepiness Scale.
A
B
Figure 3 Task-based co-activation pattern of the right basolateral amygdala/hippocampus (P<0.05, cFWE corrected) (A) and of the right 
central insula (P<0.05, cFWE corrected) (B) in sleep apnea patients (10).
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OSA, and that the structural changes observed provide a basic 
neurocognitive architectural scaffold for later reorganization 
that underscored some of the observed functional recovery 
in working and episodic memory (Figure 4). However, it has 
been also proposed that white matter changes observed 
in OSA patients may be refractory to treatment and may 
require longer treatment regimes (14), with a minimum of 
12 months of CPAP treatment needed to reverse of some 
white matter changes recorded prior to commencement of 
therapy (11).
In conclusion, OSA-induced brain injury is an increasingly 
recognised entity and should be thought of as comprising 
a wide spectrum of related, if varied, neuropsychiatric 
presentations. Their variety and severity likely reflect 
idiosyncratic susceptibility of individual patients, as well as 
the interplay with the co-morbid impact of OSA on other 
body organs and systems, such as the cardiovascular system 
and the kidneys.
OSA and renal dysfunction
CKD is a highly prevalent disorder, associated with 
increased healthcare utilisation, hospitalisation and risk 
of death (72). Recognised contributory pathologies to its 
development include type 2 diabetes mellitus (T2DM) and 
hypertension, both common co-morbidities in patients with 
OSA. OSA appears to have a bi-directional relationship 
with CKD: the pathophysiological consequences of sleep 
disordered breathing have the potential to adversely affect 
kidney function, and lead to progression of established 
CKD (73), while altered fluid dynamics in advanced renal 
disease have an established detrimental effect on sleep 
breathing (74). Below we discuss the evidence in support 
of a role for OSA in the evolution of CKD, along with the 
impact of renal failure on OSA severity.
OSA as a risk factor for CKD
A potential relationship between OSA & CKD was first 
explored in 1988 (75) where 34 patients with OSA were 
reviewed and 6 found to have significant proteinuria on 
dipstick, 3 of which were seen to be in the nephrotic range. 
None of the healthy controls who were matched for age, 
sex and weight had proteinuria. Four OSA patients were 
followed for 4 years after starting CPAP therapy and a 
reduction in proteinuria was seen with treatment. However, 
it was some time before investigators began exploring this 
field in greater detail; more recent studies have suggested an 
increased prevalence of CKD in OSA cohorts, and have also 
evaluated the potential underlying mechanisms.
A significantly higher prevalence of CKD among OSA 
patients was identified in over 9,000 Japanese subjects: CKD 
was present in 30.5% of subjects with an AHI >5 events/hour, 
compared with 9.1% of the general population (adjusted 
OR 4.5) (76). In a carefully selected cohort with severe OSA, 
but without key CKD risk factors such as hypertension and 
diabetes, prevalence of CKD was found to be around 18% (77). 
Data from a retrospective study of 161 non-obese Japanese 
patients with stage 3–4 CKD showed a relative fourfold rate 
of decline in eGFR in subjects with a 4% ODI ≥15 (78), 
while an adjusted OR of 2.89 for accelerated loss of renal 
function was observed among subjects with nocturnal 
hypoxemia (defined as spending ≥12% of study time with an 
SpO2 <90%) in another retrospective cohort study involving 
858 subjects referred to a Canadian sleep unit (79). Perhaps 
the best population-level evidence in this fields comes from 
a longitudinal study of 4674 Taiwanese patients with sleep 
disordered breathing who were compared with 23,370 age- 
and sex-matched controls; following adjustment for relevant 
confounding diagnosis and demographic factors, subjects 
with sleep apnea had a 1.94-fold risk of developing CKD 
and a 2.2-fold increase in incidence of end stage renal 
disease (ESRD) over a 5-year period (80). 
These are not uniform findings. A retrospective 
review evaluating kidney function in 634 Turkish patients 
with OSA and 62 healthy controls, compared estimated 
glomerular filtration rate (eGFR) in OSA patients with 
and without metabolic syndrome and LVH (81). Subjects 
with LVH and metabolic syndrome had a significantly 
lower eGFR when compared with OSA patients without 
these co-morbidities or with healthy controls. However, 
no significant differences were seen in eGFR in OSA 
patients without LVH or metabolic syndrome compared 
to controls, suggesting that indirect effects of OSA such 
as hypertension, precipitate renal changes and eventually 
dysfunction. Similarly, in a cross-sectional analysis of 
8,112 participants in the multi-national ESADA study, diabetes 
and hypertension were independent predictors of mild-
moderate renal impairment, while AHI and ODI were not (82).
Pathophysiology of CKD in OSA patients
Renal dysfunction in OSA patients may arise via traditional 
risk factors for CKD associated with OSA, or it may be the 
result of the characteristic pathophysiological consequences 
of sleep disordered breathing, such as increased sympathetic 
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output, oxidative stress, systemic inflammation, and 
nocturnal hypoxemia.
Conventional CKD risk factors and OSA
The relationship between OSA and cardio-metabolic 
disorders with established links to the evolution of CKD 
is the subject of an extensive and growing evidence base. 
OSA is an independent risk factor for the development of 
hypertension, and appears to have independent associations 
with the development of atherosclerosis and diabetes mellitus 
prevalence and control (83-85). The potential causative 
role of OSA in the development of these important co-
morbidities is the subject of recent dedicated reviews in the 
Journal of Thoracic Disease (7,86), and will not be discussed 
in detail here. Notably, OSA may hasten the development 
of diabetic nephropathy (DN), as evidenced by an increased 
prevalence of OSA in subjects with DN, and an increased 
rate of progression of CKD in OSA patients, in a cohort of 
224 type 2 diabetes followed over 2.5 years (87).
Another potential confounding factor in studies assessing 
the relationship between kidney disease and OSA is the effect 
of obesity on renal function. Obesity is an established risk 
factor for the presence of CKD: a meta-analysis of 19 cohorts 
evaluating the relationship between increasing body mass and 
renal function identified a pooled relative risk of 1.83 (95% CI 
1.57–2.13) for CKD among subjects with a BMI ≥30 kg/m2 
when compared with lean cohorts, following adjustment 
for relevant confounding factors (88). A case control study 
comparing renal biopsies in 95 morbidly obese patients 
undergoing bariatric surgery with 40 control subjects 
identified an independent relationship between BMI and 
likelihood of glomerular lesions (podocyte hypertrophy, 
increased mesangial cellularity or increased extracellular 
matrix) (89). Other investigators have found obesity to 
be associated with glomerular hypertrophy, basement 
membrane thickening, and overt proteinuria (90,91). 
OSA as a causative factor in CKD
Pathways through which sleep disordered breathing may 
exert a direct impact on renal function include alterations 
in glomerular perfusion mediated by OSA-related changes 
in sympathetic tone, neurohumeral output, and endothelial 
function, alongside tubulointerstitial hypoxia due to repetitive 
nocturnal fluctuations in oxygen tension (73). Low grade 
systemic inflammation promotes endothelial dysfunction and 
subsequent atherosclerosis, and occurs in OSA patients as 
a direct result of nocturnal IH (92). Similarly, IH promotes 
the generation of free oxygen radicals, with the consequent 
oxidative stress exerting a detrimental effect on the vascular 
endothelium (93), while apneic events also lead to increased 
sympathetic outflow, leading to profound alterations in 
vascular tone (94). In a study comparing healthy controls 
with newly diagnosed patients with moderate to severe 
OSA, but free of cardiovascular risk factors, the OSA 
patients showed evidence of endothelial dysfunction, 
impaired renal vasodilation and reduced endothelial nitric 
oxide synthase expression, despite a lack of overt signs of 
end organ disease. This suggests that OSA in itself is an 
independent risk factor for clinically occult renal endothelial 
damage which is not clinically detectible, which may then 
proceed to overt renal dysfunction (95).
An important potential mechanism mediating the 
development of CKD in OSA patients is activation of the 
renin-angiotensin system (RAS). Alongside increasing 
systemic blood pressure, disproportionate RAS activation 
leads to glomerular hyperperfusion and subsequent 
glomerulosclerosis. A number of studies have suggested that 
OSA may lead to systemic RAS activation, with data from 
rodent models suggesting that IH may play a key role (96). 
An elegant, sham controlled, cross-over study examined 
systemic BP changes in nine healthy subjects exposed 
variously to sham IH, IH with placebo, and IH with the 
type I angiotensin II receptor antagonist losartan. Exposure 
to IH, but not sham IH, lead to a significant increase in 
BP, an increase that was entirely abrogated by losartan, 
suggesting a key role for IH in causing alterations in RAS 
activation. 
Recently, reduced renovascular sensitivity in response to 
a 60-minute angiotensin II infusion was observed in OSA 
patients with severe nocturnal hypoxemia when compared 
with milder OSA patients and non-apneic, obese controls (97). 
No changes were observed in BP or in circulating markers 
of RAS activation, suggesting a specific direct impact of IH 
on the kidney. The effects of IH on RAS activity may be 
mediated via changes in sympathetic tone, with renovascular 
denervation in a pig model of OSA preventing apnea-
related changes in RAS activation (98).
Effect of CPAP on renal function
Were OSA contributing to the development of CKD, 
the use of nocturnal CPAP therapy might be expected 
to lead to measureable improvements in indices of renal 
RAS activation and renal function. There is evidence that 
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compliance with CPAP therapy in OSA patients with 
known renal disease can slow the progression of CKD—a 
retrospective study of 42 patients with OSA and stage 
3–5 CKD found that decline in eGFR over 2 years was 
significantly more precipitous in subjects who were poorly 
compliant with CPAP therapy (99). A week of nocturnal 
CPAP reduced glomerular hyperfiltration in 24 men with 
moderately severe OSA (100), while two studies involving 
ultrasonographic evaluation of the renal circulation in OSA 
subjects, showed a significant improvement in intra-renal 
haemodynamics after initiation of CPAP (101,102). These 
changes may be attributable to alterations in RAS activity 
following commencement of CPAP therapy; Nicholl et al 
measured changes in renal plasma flow response to infused 
angiotensin II as an indirect measure of the intrarenal RAS 
before and after one month of CPAP therapy in 20 patients, 
finding that CPAP use was associated with reduced 
circulating aldosterone levels and reduced overall intra-renal 
RAS activity (103). Overall, a growing body of evidence 
suggests that OSA may directly and indirectly contribute to 
the decline of kidney function, and that CPAP therapy may 
at least partially ameliorate this decline, although further 
interventional studies examining the effect of CPAP on 
longitudinal outcomes are required.
 CKD as a contributor to OSA severity
Sleep disordered breathing is common in CKD cohorts, and 
its prevalence increases as renal function deteriorates, with 
a study of 254 subjects representing the full spectrum of 
renal function finding that 41% of CKD patients and 57% 
of ESRD patients had significant sleep apnea, as defined 
by an RDI ≥15, compared to 27% of those with an eGFR 
≥60 mL/min/kg2 (104). In OSA, a combination of 
anatomical features, changes in ventilatory control, and 
modifiable environmental factors such as obesity lead to 
an increased propensity for upper airways collapse during 
sleep (105). In advanced CKD & ESRD these mechanisms 
also apply, but there is increasing evidence that peripheral 
volume overload and rostral fluid shift - whereby fluid shifts 
from the legs and torso towards the head and neck while 
recumbent—may be important additional contributors (74). 
Measurement of upper airway dimensions with acoustic 
pharyngometry shows that ESRD patients have reduced 
pharyngeal area when compared with subjects with normal 
renal function (106). Inducing a transient state of volume 
overload with the infusion of a high volume of isotonic 
saline solution during sleep in healthy men >40 years old 
leads to a marked increase in AHI, occurring in parallel with 
an increase of neck circumference (107). In ESRD patients, 
the extent of rostral fluid shift, as measured by changes in 
leg fluid volume, correlates with OSA severity indices, a 
relationship which survives adjustment for confounding 
variables (108). Pulmonary congestion is common in dialysis 
patients, even when relatively asymptomatic, and may lead 
to altered chemosensitivity, loop gain and reduced ventilator 
stability, potentially further increasing the severity of sleep 
disordered breathing (109,110).
While ESRD may also contribute to sleep disordered 
breathing via uremic destabilisation of central respiratory 
control (109), data from studies of varying dialysis strategies 
suggest that alterations in extravascular fluid volume 
may be of more relevance to OSA severity. Conventional 
hemodialysis (HD) does not appear to significantly 
abrogate the degree of OSA present, but switching ESRD 
patients to a nocturnal HD strategy is associated with 
marked improvements in sleep breathing (111), while renal 
transplantation may lead to resolution of sleep apnea (112). 
That volume removal, rather than metabolic changes 
occurring post-HD, is the key factor here is suggested by 
a recent elegant study of changes in sleep breathing in 15 
HD-dependent patients with moderate-severe OSA, who 
underwent PSG before and after aggressive fluid removal by 
ultra-filtration (UF) (113). Following UF, AHI was reduced 
by 36%, and a significant improvement in objective sleep 
quality was observed, with these improvements correlating 
with reductions in measures of peripheral volume overload. 
It is certainly clear that renal dysfunction is associated 
with OSA, and that OSA is found in higher incidence 
in CKD patients. However, as with all research into 
patients with OSA, there are many potential confounding 
co-morbidities which are difficult to account for when 
determining underlying mechanisms. Further larger studies 
are needed to assess whether OSA and IH directly lead to 
CKD, and therefore whether more measures need to be 
taken to monitor and treat these patients earlier to prevent 
this end organ damage, and whether all patients with CKD 
and ESRD should be screened for OSA and treated as early 
as possible to prevent further decline. 
OSA and cancer
A decade of research into the cardiovascular consequences 
of sleep disordered breathing has shown OSA to lead 
to chronic systemic inflammation, oxidative stress, and 
immune dysregulation. Alongside recurrent nocturnal 
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hypoxemia and local tissue hypoxia, these factors contribute 
to the development of an oncogenic milieu. A recognition 
of this has led to a recent spate of studies exploring how 
sleep apnea may influence cancer incidence and outcomes. 
Unusually, the evidence base in this field started with 
initial proof of concept studies in animal models of IH, 
before moving on to clinical studies confirming a potential 
causative role for OSA in carcinogenesis, but for the 
purposes of this brief review, longitudinal population studies 
shall be discussed first, before moving on to animal and 
mechanistic data.
Cancer incidence and outcomes in OSA 
populations
A number of community- and sleep laboratory-based 
population studies have found an association between 
severity of sleep disordered breathing and cancer incidence. 
In a multicentre sleep clinic cohort involving 4,910 patients 
followed for a median of 4.5 years, incidence of cancer was 
assessed across tertiles of nocturnal hypoxemia, as measured 
by the cumulative sleep time with oxygen saturations <90% 
(ct90) (114). Compared to subjects in the lowest tertile 
(ct90 <1.2%), those in the highest (ct90 >12%) had an 
adjusted HR of 2.33 for developing malignancy. This 
relationship was strongest in participants under the age of 
65 yrs. A smaller study of 400 community based Australian 
subjects found that moderate-severe OSA (RDI >15) 
predicted a 2.5-fold risk of incident cancer over a 20-year 
follow-up (115). Data from an administrative claims database 
in Taiwan examined the relationship of OSA with organ-
specific cancer risk. Among 23,055 OSA patients, the risk 
of central nervous system (CNS) malignancy was 1.5 times 
that of age- and gender-matched non-apneic controls over 
a 2-year period, with the greatest risk seen in subjects with 
both OSA and insomnia (HR 2.20) (116). A five year follow 
up of 846 women with OSA found a two-fold risk of breast 
cancer when compared to age-matched controls in a cohort 
derived from a subset of the same database (117).
Not all investigators have found a link between OSA and 
cancer risk, however. Over a mean follow-up of 13 years, 
no overall association between symptoms of sleep apnea 
and subsequent cancer risk was seen in 8,783 participants 
in the Copenhagen City Heart Study, although there was 
a relationship between subjective sleepiness and incident 
malignancy in younger subjects (118). While this study 
was limited by its lack of objective measurements of sleep 
disordered breathing, a large Canadian study of nearly 
10,000 patients undergoing in-laboratory PSG similarly 
found that any association between OSA severity and cancer 
risk appeared to be attributable to conventional risk factors, 
such as age, smoking and obesity (119). Nonetheless, even 
within this latter cohort, sub-group analyses suggested a 
link between severity of nocturnal hypoxemia and smoking-
related cancer incidence.
Fewer studies have evaluated the relationship between 
OSA and risk of cancer death. What data is available 
suggests that subjects with more severe sleep apnea are 
more likely to die of cancer than those with mild or no 
sleep disordered breathing. In a 22-year follow-up of 
1,522 participants in the community-based Wisconsin 
Sleep Cohort Study, a dose-response relationship 
between OSA severity and cancer-specific mortality was 
observed, with severe OSA conferring a nearly five-
fold risk of death from cancer (adjusted RR 4.8) (120). 
This relationship was particularly strong in those with 
the most severe degree of nocturnal hypoxemia, and 
in non-obese subjects. Participants in the Australian 
Busselton Health Study had a 3.4-fold risk of cancer 
dea th  i f  they  had  modera t e - s eve re  OSA (115 ) , 
while data from Spanish sleep laboratory patients 
followed for an average of 4.5 years demonstrated 
an increased risk of death with increasing degrees of 
nocturnal hypoxemia, particularly in patients <65 years 
of age (121). A summary of population and clinical studies 
of cancer incidence and death in OSA patients is presented 
in Table 1.
Cancer and OSA in animal models and clinical 
studies
Initial studies evaluating interactions between OSA and 
cancer were largely performed in animal models of IH. In a 
ground-breaking series of studies, Almendros et al. showed 
that IH had a clear detrimental effect in mice inoculated 
with melanoma cells. In animals where melanoma was 
induced by injection of malignant cells into the flank, 
exposure to 17 days of IH for 6 hours/day was associated 
with an increased rate of tumour growth, which occurred 
in parallel with increased circulating levels of vasoactive 
endothelial growth factor (VEGF) (122). Moreover, 30 days 
of IH lead to an increased number and volume of 
pulmonary metastases when compared to control mice (123). 
A similar study protocol using epithelial lung tumour cells 
also showed increased rates of cancer progression in IH-
exposed animals (124), while other OSA-related factors, 
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such as sleep fragmentation, have similarly been shown to 
accelerate tumour growth in murine IH models (125).
There is at present a paucity of clinical studies 
examining the effect of OSA on cancer progression. 
In a multicentre observational studies of 82 patients 
diagnosed with cutaneous melanoma, OSA severity indices 
independently predicted tumour growth rate, along with 
other indicators of aggressiveness. These findings need to 
be confirmed in other clinic populations, and it is as yet 
unknown if CPAP therapy could have a modifying role in 
cancer outcomes.
Mechanisms of carcinogenesis in OSA
Systemic inflammation and oxidative stress
There is a longstanding recognition that any disorder 
associated with chronic local or systemic inflammation may 
be associated with an increased risk of cancer development, 
an effect potentially mediated or amplified by the generation 
of reactive oxygen and reactive nitrogen species, with 
associated DNA damage and impaired DNA repair (126). 
OSA and associated IH have been demonstrated to 
Table 1 Population studies of associations between OSA and cancer incidence and death
Authors (ref.) Participants Study design Outcome measures Findings
Campos-Rodriguez 
et al. (114)
4,910 subjects Observational Cancer incidence according to 
degree of nocturnal hypoxemia 
Increased cancer incidence over  
4.5 yrs with increasing hypoxemia
Clinic based – Attended inpatient sleep studies HR 2.2 for incident cancer if CT90 >12%
Christensen  
et al. (118)
8,783 subjects Observational Cancer incidence according to 
presence of OSA symptoms
No overall relationship between OSA and 
cancer incidence over 13 yrs 
Community 
based
– SDB symptoms identified by 
questionnaire
Increased alcohol related cancer 
incidence in sleepy subjects
Chen  
et al. (116)
92,220 
subjects
Historical cohort CNS cancer incidence according 
to OSA diagnosis
Increased incidence of CNS cancer in 
OSA over 10 yrs (HR 1.54)
Community 
based
– Data abstracted from 
administrative claims database
Highest risk in OSA with insomnia (HR 2.20)
Chang  
et al. (117)
5,076 female 
subjects
Historical cohort Breast cancer incidence 
according to OSA diagnosis
Increased incidence of breast cancer in 
OSA over 5 years (HR 2.09)
Community 
based
– Data abstracted from 
administrative claims database
Kendzerska  
et al. (119)
9,629 subjects Historical cohort Cancer incidence from cancer 
registry according to OSA 
severity
No significant relationship between OSA 
and cancer incidence 
Clinic based – Significant association between 
hypoxemia and smoking related cancer
Marshall  
et al. (115)
400 subjects Observational Cancer incidence and mortality Increased cancer incidence with moderate-
severe OSA over 20 years (HR 2.5)
Community 
based
– Home cardio-respiratory 
polygraphy
Increased cancer related mortality with 
moderate-severe OSA (HR 3.4)
Nieto  
et al. (120)
1,522 subjects Observational Cancer mortality Increased cancer-specific mortality with 
severe OSA (HR 4.8)
Community 
based
– Attended inpatient PSG Markedly increased cancer-specific 
mortality with nocturnal hypoxemia (HR 8.6)
CT90, cumulative sleep time with SpO2 <90%; HR, hazard ratio; OSA, obstructive sleep apnea; CNS, central nervous system; PSG, 
polysomnography.
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independently contribute to the development of low-grade 
systemic inflammation (6), with increased expression of NF-κB 
dependent cytokines in both clinical subjects (127) and in vitro 
models of disease (128). Similarly, a significant evidence base 
supports the notion that OSA is an oxidative stress disorder, 
with reactive oxygen and nitrogen species likely formed at least 
partially due to IH-mediated mitochondrial dysfunction (93). 
Nocturnal CPAP therapy may lead to an abrogation of both 
systemic inflammation and oxidative stress, suggesting that 
appropriate treatment may obviate any pro-carcinogenic 
effect of OSA.
Hypoxemia and tissue hypoxia
Local tissue hypoxia induces stability of hypoxia-inducible 
factor-1α (HIF-1α), which under normoxic conditions is 
degraded by a series proline hydroxylases (129). In general 
terms, this can be considered an adaptive process, with 
HIF acting as a master regulator of cellular responses to 
decreased oxygen supply or increased oxygen consumption, 
but it appears to play a key maladaptive role in tumour 
biology (130). HIF-1 dependent-genes promote cell 
proliferation and angiogenesis, and facilitate metabolic 
adaptation to the hypoxic environment, thereby promoting 
tumour survival and progression (130). While OSA leads to 
intermittent hypoxemia, it is unclear if this translates into 
intermittent or sustained hypoxia at a tissue level. Rodent 
data would suggest that severe chronic IH may lead to 
fluctuating oxygen levels in hepatic tissue, but sustained 
hypoxia in adipose tissue (131). Human data are lacking, 
but sustained tissue hypoxia leads to a robust increase in 
expression of HIF-dependent genes, perhaps promoting 
carcinogenesis. Moreover, hypoxia is a pro-inflammatory 
stimulus, with HIF and NF-κB interacting to drive 
increased inflammatory cytokine expression (132,133). 
Sleep fragmentation and increased sympathetic drive
Generally considered to be mediators of the adverse 
cardiovascular consequences of sleep disordered breathing, 
sleep fragmentation and increased sympathetic tone induced 
by apneic events may also contribute to cancer development. 
As mentioned above, animal models of sleep fragmentation 
lead to increased tumour progression; the potential 
immunological mechanisms behind this will be discussed 
below (125). Sleep disruption and restriction seen in shift 
workers are also associated with an increased risk of cancer 
incidence (134), but specific data examining the relationship 
between sleep fragmentation per se and cancer are lacking (135). 
Increased adrenergic signalling may also promote cancer 
survival and growth, although there is again a paucity of 
evidence specific to OSA patients in this regard (135). 
Alterations in immune function
A key effector cell in cancer biology is the macrophage, 
and robust evidence shows that an increase in tumour 
associated macrophages (TAMs), particularly those with 
an anti-inflammatory M2 phenotype, is associated with 
worse outcomes in a variety of cancers (136). TAMs appear 
to promote angiogenesis, and promote tumour invasion 
and metastatic capacity. In a murine model of IH, TAMs 
showed a shift in polarity to a pro-tumoural M2 phenotype, 
and TAMs explanted from IH-exposed mice enhanced 
proliferation and invasiveness of pulmonary epithelial 
cancer cells in vitro (124,137). 
Data examining tumour-specific immune function in 
OSA patients also suggests that sleep disordered breathing 
may contribute to a reduction in innate anti-tumoural 
responses. Genome sequencing in circulating leucocytes 
harvested from treatment-naïve patient with severe OSA 
revealed an upregulation in pro-neoplastic gene sets (138), 
and a subsequent downregulation in expression of these 
genes following approximately one month of CPAP therapy.
Another important effector cell in host responses to 
tumour development is the invariant natural killer T cell 
(iNKT). These are potent immunomodulatory cells which 
play a key role in conducting both innate and adaptive 
immune responses, and which have been demonstrated 
to direct anti-tumour responses and to directly lyse 
tumour cells (139). A recent novel study found a marked 
reduction in circulating iNKT cells in patients with severe 
OSA, correlating directly with indices of OSA severity 
independently of the confounding effects of obesity (140). 
Furthermore, a year of CPAP therapy lead to a partial 
restoration in iNKT numbers, and a series of in vitro 
models showed that hypoxia lead to a reduction in their 
ability to lyse tumour cells. 
Overall, circumstantial, epidemiological and animal-
based data support  a  role for OSA in promoting 
carcinogenesis and cancer progression. However, further 
mechanistic studies are required to better understand 
the underlying molecular alterations that underpin 
this association, and large scale, well designed trials of 
CPAP therapy will be required to demonstrate that OSA 
constitutes a modifiable risk factor for cancer development.
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Conclusions
The relationship between OSA and cardiovascular 
morbidity is well established, and it seems increasingly 
likely that sleep disordered breathing also promotes 
the development of metabolic disease. However, the 
pathophysiological effects of OSA appear to extend beyond 
the vasculature and endocrine function, with a growing 
evidence base suggesting that it is of significant relevance in 
neurocognitive functioning, the development of CKD, and 
cancer risk and outcomes. As emphasised above, all three 
of these areas represent emerging fields, and ongoing high 
quality studies are required to further our understanding of 
the processes concerned.
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